menu
    • menu
    [{"orgOrder":0,"company":"Cessation Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"CSX-1004","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cessation Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Cessation Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cessation Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cessation Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"CSX-1004","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cessation Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cessation Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cessation Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cessation Therapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"CSX-1004","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Cessation Therapeutics","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"","sponsorNew":"Cessation Therapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"Cessation Therapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Cessation Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"CSX-1004","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cessation Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cessation Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cessation Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Cessation Therapeutics

    Menu

    Cessation Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cessation Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Cessation Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CSX-1004

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cessation Therapeutics Receives FDA Fast Track Designation for CSX-1004 for Prevention of Fentanyl and Fentany...

                            Details : CSX-1004 is a human IgG1 monoclonal antibody under phase 1 clinical studies, it is specific for fentanyl and fentanyl analogs and works by sequestering fentanyl molecules & effectively neutralizing them in the blood before they reach the brain.

                            Brand Name : CSX-1004

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 31, 2023

                            Lead Product(s) : CSX-1004

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cessation Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Cessation Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CSX-1004

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : IND Enabling

                            Sponsor : National Institute on Drug Abuse

                            Deal Size : $14.8 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Cessation Therapeutics Awarded $14.8 Million Grant from the National Institute of Drug Abuse to Develop Novel ...

                            Details : The funding will support development of a subcutaneous formulation of its anti-fentanyl monoclonal antibody, CSX-1004 SQ, an investigational product that has successfully entered Phase 1 studies for the reversal of acute opioid over dose of fentanyl and ...

                            Brand Name : CSX-1004

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 18, 2023

                            Lead Product(s) : CSX-1004

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : IND Enabling

                            Sponsor : National Institute on Drug Abuse

                            Deal Size : $14.8 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cessation Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Cessation Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CSX-1004

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cessation Therapeutics Announces Food and Drug Administration Authorization for First-in-Human Clinical Trial ...

                            Details : CSX-1004 is a recombinant human immunoglobulin G (IgG)1λ monoclonal antibody specific for fentanyl and related synthetic opioids. CSX-1004 is the first antibody-based therapy against fentanyl to gain IND approval.

                            Brand Name : CSX-1004

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 27, 2023

                            Lead Product(s) : CSX-1004

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cessation Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Cessation Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CSX-1004

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cessation Therapeutics’ Anti-Fentanyl Monoclonal Antibody Treatment Shows Promise in Protecting Against Fent...

                            Details : CSX-1004 is a human antibody that binds to fentanyl and related synthetic opioids tightly and with high-specificity. It has been demonstrated to provide multi-week protection from fentanyl overdose during animal studies.

                            Brand Name : CSX-1004

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 28, 2023

                            Lead Product(s) : CSX-1004

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth